Scroll

etravirine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)	1115	269055-15-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: etravirine intelence etravirin R-165335 TMC-125	HIV-1 reverse transriptase inhibitor; an anti-HIV agent Molecular weight: 435.29 Formula: C20H15BrN6O CLOGP: 5.17 LIPINSKI: 1 HAC: 7 HDO: 2 TPSA: 120.64 ALOGS: -4.41 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

etravirine
intelence
etravirin
R-165335
TMC-125

HIV-1 reverse transriptase inhibitor; an anti-HIV agent

Molecular weight: 435.29
Formula: C20H15BrN6O
CLOGP: 5.17
LIPINSKI: 1
HAC: 7
HDO: 2
TPSA: 120.64
ALOGS: -4.41
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.56 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Aug. 28, 2008	EMA
Jan. 18, 2008	FDA	JANSSEN R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Enlarged clitoris	208.51	43.20	28	2401	130	63486463
Hyperandrogenism	191.70	43.20	25	2404	88	63486505
Viral mutation identified	170.79	43.20	33	2396	1777	63484816
Foetal exposure during pregnancy	167.73	43.20	58	2371	31904	63454689
Exposure during pregnancy	167.41	43.20	92	2337	155455	63331138
Virologic failure	145.51	43.20	29	2400	1833	63484760
Lipodystrophy acquired	127.92	43.20	25	2404	1427	63485166
Cloacal exstrophy	109.37	43.20	16	2413	150	63486443
Congenital genital malformation	102.49	43.20	15	2414	141	63486452
Bladder agenesis	102.21	43.20	15	2414	144	63486449
Genitalia external ambiguous	101.56	43.20	15	2414	151	63486442
Caudal regression syndrome	100.60	43.20	15	2414	162	63486431
Meconium stain	98.69	43.20	15	2414	186	63486407
Abortion spontaneous	98.68	43.20	44	2385	47151	63439442
Gastrointestinal disorder congenital	95.81	43.20	14	2415	130	63486463
Anal atresia	95.38	43.20	16	2413	382	63486211
Tethered cord syndrome	93.51	43.20	15	2414	269	63486324
Meningomyelocele	88.35	43.20	16	2413	602	63485991
Gastrointestinal malformation	84.54	43.20	13	2416	175	63486418
Exomphalos	83.42	43.20	15	2414	542	63486051
Umbilical cord abnormality	80.81	43.20	15	2414	648	63485945
Premature baby	79.95	43.20	30	2399	20705	63465888
Immune reconstitution inflammatory syndrome	69.38	43.20	20	2409	6064	63480529
Premature labour	66.66	43.20	23	2406	12481	63474112
Pathogen resistance	64.00	43.20	19	2410	6379	63480214
Drug resistance	63.12	43.20	26	2403	22907	63463686
Neural tube defect	61.68	43.20	10	2419	192	63486401
Congenital ectopic bladder	60.28	43.20	9	2420	98	63486495
Anencephaly	57.50	43.20	10	2419	297	63486296
Congenital anomaly	55.40	43.20	13	2416	1763	63484830
Spina bifida	53.00	43.20	11	2418	848	63485745
Sepsis neonatal	46.86	43.20	9	2420	467	63486126
Treatment noncompliance	45.26	43.20	24	2405	37301	63449292
Amniotic cavity infection	43.39	43.20	10	2419	1253	63485340

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	470.08	24.40	106	4802	3238	34948785
Mitochondrial toxicity	414.52	24.40	92	4816	2607	34949416
Progressive external ophthalmoplegia	387.61	24.40	78	4830	1357	34950666
Eyelid ptosis	349.86	24.40	93	4815	5673	34946350
Diplopia	233.38	24.40	88	4820	16755	34935268
Virologic failure	219.87	24.40	58	4850	3422	34948601
Drug interaction	155.97	24.40	174	4734	225772	34726251
Viral mutation identified	120.78	24.40	35	4873	2919	34949104
Ophthalmoplegia	103.54	24.40	28	4880	1812	34950211
Drug resistance	100.99	24.40	56	4852	25871	34926152
Pathogen resistance	71.17	24.40	32	4876	9450	34942573
CD4 lymphocytes decreased	59.66	24.40	18	4890	1723	34950300
Cytomegalovirus chorioretinitis	54.17	24.40	20	4888	3569	34948454
Fibrous histiocytoma	49.73	24.40	10	4898	172	34951851
Viral load increased	49.16	24.40	17	4891	2510	34949513
Adrenal suppression	46.71	24.40	12	4896	635	34951388
Drug level increased	43.54	24.40	31	4877	22065	34929958
Immune reconstitution inflammatory syndrome	42.73	24.40	22	4886	8737	34943286
Multiple-drug resistance	37.15	24.40	17	4891	5222	34946801
Heart transplant rejection	34.87	24.40	11	4897	1220	34950803
Renal tubular disorder	32.71	24.40	15	4893	4628	34947395
Hepatic steatosis	32.17	24.40	24	4884	18338	34933685
Hepatic cirrhosis	31.16	24.40	23	4885	17291	34934732
Drug level decreased	30.65	24.40	17	4891	7829	34944194
Blood creatine phosphokinase abnormal	30.28	24.40	7	4901	237	34951786
Osteoporosis	30.21	24.40	20	4888	12648	34939375
Hepatitis C	29.64	24.40	18	4890	9812	34942211
Hepatitis	28.61	24.40	25	4883	23879	34928144
Opportunistic infection	27.85	24.40	10	4898	1648	34950375
Choroiditis	26.87	24.40	9	4899	1206	34950817
Viraemia	26.71	24.40	9	4899	1229	34950794

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	554.03	26.20	112	5357	4213	79734706
Mitochondrial toxicity	460.95	26.20	91	5378	3023	79735896
Progressive external ophthalmoplegia	449.48	26.20	79	5390	1366	79737553
Eyelid ptosis	341.48	26.20	90	5379	10954	79727965
Virologic failure	282.62	26.20	64	5405	4127	79734792
Viral mutation identified	255.19	26.20	58	5411	3800	79735119
Diplopia	235.87	26.20	88	5381	33378	79705541
Drug interaction	176.93	26.20	177	5292	415006	79323913
Drug resistance	125.08	26.20	60	5409	42153	79696766
Ophthalmoplegia	105.75	26.20	27	5442	2885	79736034
Pathogen resistance	105.64	26.20	39	5430	14303	79724616
Immune reconstitution inflammatory syndrome	88.72	26.20	34	5435	13807	79725112
Multiple-drug resistance	65.03	26.20	24	5445	8784	79730135
Abortion spontaneous	61.24	26.20	33	5436	29474	79709445
Exposure during pregnancy	59.88	26.20	52	5417	101080	79637839
Adrenal suppression	50.93	26.20	13	5456	1386	79737533
Hepatic cirrhosis	43.31	26.20	28	5441	34878	79704041
Fibrous histiocytoma	43.18	26.20	10	5459	709	79738210
Blood HIV RNA increased	43.01	26.20	12	5457	1796	79737123
Renal tubular disorder	41.79	26.20	16	5453	6470	79732449
Treatment noncompliance	41.71	26.20	32	5437	52236	79686683
Hepatitis C	41.61	26.20	19	5450	11906	79727013
Genotype drug resistance test positive	37.24	26.20	10	5459	1298	79737621
Drug level decreased	32.39	26.20	17	5452	14385	79724534
Choroiditis	32.09	26.20	9	5460	1372	79737547
Mycobacterium avium complex infection	31.99	26.20	12	5457	4588	79734331
Hepatic steatosis	29.87	26.20	23	5446	37715	79701204
Hepatitis	29.66	26.20	27	5442	55700	79683219
Premature labour	28.12	26.20	13	5456	8377	79730542
Oesophageal candidiasis	26.95	26.20	13	5456	9205	79729714
Amniotic cavity infection	26.77	26.20	7	5462	820	79738099
Anogenital dysplasia	26.40	26.20	5	5464	132	79738787
CD4 lymphocytes decreased	26.36	26.20	9	5460	2625	79736294
Lipohypertrophy	26.31	26.20	7	5462	877	79738042

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AG04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors
FDA MoA	N0000009948	Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT	N0000175460	Non-Nucleoside Analog
FDA EPC	N0000175463	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors
FDA MoA	N0000190118	Cytochrome P450 3A Inducers
CHEBI has role	CHEBI:22587	antiviral agents
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Chronic type B viral hepatitis	contraindication	61977001
Chronic hepatitis C	contraindication	128302006
Liver function tests abnormal	contraindication	166603001
Peripheral nerve disease	contraindication	302226006
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.78	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Canalicular multispecific organic anion transporter 1	Transporter	Q92887	MRP2_HUMAN		IC50	5.11	CHEMBL
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN		IC50	5.07	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.22	CHEMBL
Canalicular multispecific organic anion transporter 2	Transporter	O15438	MRP3_HUMAN		IC50	5.29	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.12	CHEMBL
Reverse transcriptase/RNaseH	Enzyme		Q72547_9HIV1	INHIBITOR	IC50	9.22	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1A2		IC50	9	WOMBAT-PK
Cruzipain	Enzyme		CYSP_TRYCR		IC50	5.40	CHEMBL
Reverse transcriptase	Enzyme		Q9WKE8_9HIV1		IC50	8	CHEMBL
Reverse transcriptase protein	Unclassified		Q9WJQ2_9HIV1		IC50	8.89	CHEMBL

External reference:

ID	Source
4027244	VUID
N0000179781	NUI
D04112	KEGG_DRUG
4027244	VANDF
C1456409	UMLSCUI
CHEBI:63589	CHEBI
65B	PDB_CHEM_ID
CHEMBL308954	ChEMBL_ID
DB06414	DRUGBANK_ID
C451734	MESH_SUPPLEMENTAL_RECORD_UI
12675	IUPHAR_LIGAND_ID
8303	INN_ID
0C50HW4FO1	UNII
193962	PUBCHEM_CID
475969	RXNORM
130981	MMSL
24971	MMSL
348481	MMSL
d07076	MMSL
012527	NDDF
432121008	SNOMEDCT_US
432221004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-473	TABLET	100 mg	ORAL	ANDA	25 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-474	TABLET	200 mg	ORAL	ANDA	25 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0787	TABLET	100 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5864	TABLET	100 mg	ORAL	NDA	30 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6368	TABLET	200 mg	ORAL	NDA	30 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-570	TABLET	100 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-570	TABLET	100 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-570	TABLET	100 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-571	TABLET	200 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-571	TABLET	200 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-571	TABLET	200 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-572	TABLET	25 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-572	TABLET	25 mg	ORAL	NDA	31 sections
Intelence	HUMAN PRESCRIPTION DRUG LABEL	1	59676-572	TABLET	25 mg	ORAL	NDA	31 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1720	TABLET	25 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1720	TABLET	25 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1721	TABLET	100 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1721	TABLET	100 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1722	TABLET	200 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	60219-1722	TABLET	200 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1720	TABLET	25 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1721	TABLET	100 mg	ORAL	ANDA	26 sections
etravirine	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1722	TABLET	200 mg	ORAL	ANDA	26 sections
ETRAVIRINE	HUMAN PRESCRIPTION DRUG LABEL	1	69315-285	TABLET	100 mg	ORAL	ANDA	22 sections
ETRAVIRINE	HUMAN PRESCRIPTION DRUG LABEL	1	69315-286	TABLET	200 mg	ORAL	ANDA	22 sections
ETRAVIRINE	HUMAN PRESCRIPTION DRUG LABEL	1	80005-112	TABLET	100 mg	ORAL	ANDA	22 sections
ETRAVIRINE	HUMAN PRESCRIPTION DRUG LABEL	1	80005-113	TABLET	200 mg	ORAL	ANDA	22 sections